<p><strong>新加坡，2026 年 1 月 13 日（环球新闻通讯社）--</strong> EUDA Health Holdings Limited（纳斯达克：EUDA）（“EUDA” 或 “公司”）是一家总部位于新加坡的非侵入性医疗保健提供商，专注于新加坡、马来西亚和中国。今天宣布其全资子公司 EUDA Health Pte. Ltd.（“EUDA Health”）已与深圳英诺免疫科技有限公司（“深圳英诺”）签署了一项可转换贷款协议，深圳英诺是一家开发自体细胞治疗和针对中国多种疾病的定制药物的公司。</p>
<p><strong>战略投资与设施扩展计划</strong></p>
<p>根据协议条款，EUDA 预计将分两期投资最多 600 万元人民币，其中第一期为 100 万元人民币，第二期为 500 万元人民币，具体投资将取决于尽职调查的完成、监管批准和最终协议的签署。</p>
<p>深圳英诺将利用这笔资金升级其位于深圳的 cGMP 设施，以创建一个先进的干细胞治疗生产和创新中心。该设施预计将作为 EUDA 在中国战略的核心技术和运营中心，支撑 EUDA 的再生医学能力，支持国际合作，并提供可复制的平台以扩展到其他城市和市场。</p>
<p>该投资以可转换贷款票据的形式结构，提供 EUDA 将其转换为深圳英诺股权的选择权，转换时的所有权比例将根据估值和最终文件确定。可转换贷款票据的年利率预计为 6%，按半年支付，如果未转换，可以连同应计利息赎回，具体条款以最终条款为准。</p>
<p>深圳英诺运营着一个专注于先进人类细胞处理、质量控制细胞培养、精确生物工作流程和受监管实验室操作的干细胞技术和治疗平台，支持自然杀伤细胞、γδ T 细胞、细胞因子诱导的杀伤细胞、间充质干细胞、诱导多能干细胞和类器官基础项目。该平台整合了生物处理基础设施、质量和合规系统，以及旨在支持临床和研究应用的可扩展操作流程。</p>
<p><strong>深圳英诺 – 强大的机构支持</strong></p>
<p>2017 年 8 月，HSG 资本集团（“HSG”），前身为红杉资本中国，一家领先的国际风险投资和私募股权公司，战略性地向深圳英诺投资了约 800 万美元。这笔资金为其科学平台、监管基础、长期商业潜力提供了早期的机构验证，并支持其实验室基础设施、质量系统和核心技术团队的发展。</p>
<p><strong>EUDA 首席执行官阿尔弗雷德·林先生评论道：</strong></p>
<p>“该协议反映了我们在建立长期干细胞治疗平台方面的严谨方法。通过支持高质量平台的升级和扩展，采用分阶段和灵活的投资结构，我们可以验证执行，调整我们的战略，并为更深层次的所有权和整合奠定基础。这使 EUDA 不仅成为医疗保健提供者，还成为一个具有技术、基础设施和运营深度的垂直整合平台。”</p>
<p><strong>关于 EUDA Health Holdings Limited</strong></p>
<p>EUDA Health Holdings Limited（纳斯达克：EUDA）是一家总部位于新加坡的领先非侵入性医疗保健提供商，专注于新加坡、马来西亚和中国。公司旨在成为非侵入性和预防性医疗保健的市场领导者，战略重点放在快速增长的长寿领域。我们的使命是满足超过 18 亿人不断变化的医疗保健需求，该地区正经历显著的人口结构变化，超过 30% 的人口迅速老龄化。通过提供创新、可及且有科学依据的健康解决方案，EUDA 有望引领区域医疗保健从反应性医疗转向以长寿为中心的主动护理。EUDA 还经营一家总部位于新加坡的物业管理业务。</p>
<p><strong>前瞻性声明</strong></p>
<p>本文件可能包含关于风险和不确定性的前瞻性声明。这些声明通常使用前瞻性词汇，例如 “估计”、“预测”、“预计”、“设想”、“预期”、“预测”、“计划”、“打算”、“相信”、“寻求”、“可能”、“将”、“应该”、“未来”、“提议” 及这些词或类似表达的变体（或这些词或表达的否定版本）。这些前瞻性声明并不保证未来的表现、条件或结果，并涉及许多已知和未知的风险、不确定性、假设和其他重要因素，其中许多超出了 EUDA 的控制范围，可能导致实际结果或结果与前瞻性声明中讨论的内容有实质性差异。您不应过度依赖仅适用于本文件发布之日的前瞻性声明。公司不承担任何更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，法律要求的除外。</p>
<p>Christensen Advisory</p>
<p>Christian Arnell</p>
<p>电话：+ 852 9040 0621</p>
<p>电子邮件：christian.arnell@christensencomms.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5EY3lNeU0zTXpVNE5UZzJJelV3TURFeU5EUXpPUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5EY3lNeU0zTXpVNE5UZzJJelV3TURFeU5EUXpPUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWMyYmUxYjMtNDRhMS00NWRjLWJiOGMtNGQwNDFiYWZlNmYxLTUwMDEyNDQzOS0yMDI2LTAxLTEzLWVu/tiny/EUDA-Health-Holdings-Ltd.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWMyYmUxYjMtNDRhMS00NWRjLWJiOGMtNGQwNDFiYWZlNmYxLTUwMDEyNDQzOS0yMDI2LTAxLTEzLWVu/tiny/EUDA-Health-Holdings-Ltd.png"/></p>

EUDA

<p>EUDA Health Holdings Limited 已与深圳英诺免疫有限公司签署了一项可转换贷款协议，投资金额最高可达 600 万元人民币，用于升级深圳英诺的 cGMP 设施。此次投资旨在增强 EUDA 的干细胞治疗平台，并支持其在中国的扩展战略。该贷款的利率为 6%，并为 EUDA 提供了转换为深圳英诺股权的选项。首席执行官 Alfred Lim 强调了该协议在建立长期干细胞治疗平台方面的战略重要性</p>

<p><strong>SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) --</strong> EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutics and customised medicines for a wide range of diseases in China.</p>
<div class="lb-trans"><p><strong>新加坡，2026 年 1 月 13 日（环球新闻通讯社）--</strong> EUDA Health Holdings Limited（纳斯达克：EUDA）（“EUDA” 或 “公司”）是一家总部位于新加坡的非侵入性医疗保健提供商，专注于新加坡、马来西亚和中国。今天宣布其全资子公司 EUDA Health Pte. Ltd.（“EUDA Health”）已与深圳英诺免疫科技有限公司（“深圳英诺”）签署了一项可转换贷款协议，深圳英诺是一家开发自体细胞治疗和针对中国多种疾病的定制药物的公司。</p>
</div><p><strong>Strategic Investment and Facility Expansion Plan</strong></p>
<div class="lb-trans"><p><strong>战略投资与设施扩展计划</strong></p>
</div><p>Under the terms of the agreement, EUDA expects to invest up to RMB 6 million in two tranches, consisting of an initial tranche of RMB 1 million and a second tranche of RMB 5 million, subject to the completion of due diligence, regulatory approvals, and execution of definitive agreements.</p>
<div class="lb-trans"><p>根据协议条款，EUDA 预计将分两期投资最多 600 万元人民币，其中第一期为 100 万元人民币，第二期为 500 万元人民币，具体投资将取决于尽职调查的完成、监管批准和最终协议的签署。</p>
</div><p>Shenzhen Inno will deploy the capital to upgrade its cGMP facility in Shenzhen to create a state-of-the-art production and innovation center for stem cell treatments. The facility is expected to serve as a core technology and operating hub for EUDA’s China strategy, anchoring EUDA’s regenerative medicine capabilities, supporting international collaborations, and providing a replicable platform for expansion into additional cities and markets.</p>
<div class="lb-trans"><p>深圳英诺将利用这笔资金升级其位于深圳的 cGMP 设施，以创建一个先进的干细胞治疗生产和创新中心。该设施预计将作为 EUDA 在中国战略的核心技术和运营中心，支撑 EUDA 的再生医学能力，支持国际合作，并提供可复制的平台以扩展到其他城市和市场。</p>
</div><p>The investment is structured as a convertible loan note that provides the optionality for EUDA to convert into equity interest in Shenzhen Inno, with the resulting ownership percentage to be determined at the time of conversion based on valuation and definitive documentation. The convertible loan note is expected to carry an interest rate of 6% per annum, payable semi-annually, and may be redeemed with accrued interest if not converted, subject to the final terms.</p>
<div class="lb-trans"><p>该投资以可转换贷款票据的形式结构，提供 EUDA 将其转换为深圳英诺股权的选择权，转换时的所有权比例将根据估值和最终文件确定。可转换贷款票据的年利率预计为 6%，按半年支付，如果未转换，可以连同应计利息赎回，具体条款以最终条款为准。</p>
</div><p>Shenzhen Inno operates a stem cell technology and therapy platform focused on advanced human cell processing, quality controlled cell culture, precision biological workflows and regulated laboratory operations supporting natural killer cell, gamma delta T cell, cytokine induced killer cell, mesenchymal stem cell, induced pluripotent stem cell and organoid based programs. The platform integrates biological processing infrastructure, quality and compliance systems, and scalable operating processes designed to support both clinical and research applications.</p>
<div class="lb-trans"><p>深圳英诺运营着一个专注于先进人类细胞处理、质量控制细胞培养、精确生物工作流程和受监管实验室操作的干细胞技术和治疗平台，支持自然杀伤细胞、γδ T 细胞、细胞因子诱导的杀伤细胞、间充质干细胞、诱导多能干细胞和类器官基础项目。该平台整合了生物处理基础设施、质量和合规系统，以及旨在支持临床和研究应用的可扩展操作流程。</p>
</div><p><strong>Shenzhen Inno – Strong Institutional Backing</strong></p>
<div class="lb-trans"><p><strong>深圳英诺 – 强大的机构支持</strong></p>
</div><p>In August 2017, HSG Capital Group (“HSG”), formerly known as Sequoia Capital China, a leading international venture capital and private equity firm, strategically invested approximately US$8 million in Shenzhen Inno. The capital provided early institutional validation of its scientific platform, regulatory foundation, long term commercial potential, and supported the development of its laboratory infrastructure, quality systems and core technical team.</p>
<div class="lb-trans"><p>2017 年 8 月，HSG 资本集团（“HSG”），前身为红杉资本中国，一家领先的国际风险投资和私募股权公司，战略性地向深圳英诺投资了约 800 万美元。这笔资金为其科学平台、监管基础、长期商业潜力提供了早期的机构验证，并支持其实验室基础设施、质量系统和核心技术团队的发展。</p>
</div><p><strong>Mr Alfred Lim, Chief Executive Officer of EUDA, commented:</strong></p>
<div class="lb-trans"><p><strong>EUDA 首席执行官阿尔弗雷德·林先生评论道：</strong></p>
</div><p>“This agreement reflects our disciplined approach to building long-term stem cell therapy platforms. By supporting the upgrade and expansion of a high-quality platform using a phased and flexible investment structure, we can validate execution, align our strategies, and create the foundation for deeper ownership and integration over time. This positions EUDA not only as a healthcare provider, but as a vertically integrated platform with technology, infrastructure and operational depth.”</p>
<div class="lb-trans"><p>“该协议反映了我们在建立长期干细胞治疗平台方面的严谨方法。通过支持高质量平台的升级和扩展，采用分阶段和灵活的投资结构，我们可以验证执行，调整我们的战略，并为更深层次的所有权和整合奠定基础。这使 EUDA 不仅成为医疗保健提供者，还成为一个具有技术、基础设施和运营深度的垂直整合平台。”</p>
</div><p><strong>About EUDA Health Holdings Limited</strong></p>
<div class="lb-trans"><p><strong>关于 EUDA Health Holdings Limited</strong></p>
</div><p>EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.</p>
<div class="lb-trans"><p>EUDA Health Holdings Limited（纳斯达克：EUDA）是一家总部位于新加坡的领先非侵入性医疗保健提供商，专注于新加坡、马来西亚和中国。公司旨在成为非侵入性和预防性医疗保健的市场领导者，战略重点放在快速增长的长寿领域。我们的使命是满足超过 18 亿人不断变化的医疗保健需求，该地区正经历显著的人口结构变化，超过 30% 的人口迅速老龄化。通过提供创新、可及且有科学依据的健康解决方案，EUDA 有望引领区域医疗保健从反应性医疗转向以长寿为中心的主动护理。EUDA 还经营一家总部位于新加坡的物业管理业务。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>本文件可能包含关于风险和不确定性的前瞻性声明。这些声明通常使用前瞻性词汇，例如 “估计”、“预测”、“预计”、“设想”、“预期”、“预测”、“计划”、“打算”、“相信”、“寻求”、“可能”、“将”、“应该”、“未来”、“提议” 及这些词或类似表达的变体（或这些词或表达的否定版本）。这些前瞻性声明并不保证未来的表现、条件或结果，并涉及许多已知和未知的风险、不确定性、假设和其他重要因素，其中许多超出了 EUDA 的控制范围，可能导致实际结果或结果与前瞻性声明中讨论的内容有实质性差异。您不应过度依赖仅适用于本文件发布之日的前瞻性声明。公司不承担任何更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，法律要求的除外。</p>
</div><p>Christensen Advisory</p>
<div class="lb-trans"><p>Christensen Advisory</p>
</div><p>Christian Arnell</p>
<div class="lb-trans"><p>Christian Arnell</p>
</div><p>Phone: + 852 9040 0621</p>
<div class="lb-trans"><p>电话：+ 852 9040 0621</p>
</div><p>Email: christian.arnell@christensencomms.com</p>
<div class="lb-trans"><p>电子邮件：christian.arnell@christensencomms.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5EY3lNeU0zTXpVNE5UZzJJelV3TURFeU5EUXpPUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWMyYmUxYjMtNDRhMS00NWRjLWJiOGMtNGQwNDFiYWZlNmYxLTUwMDEyNDQzOS0yMDI2LTAxLTEzLWVu/tiny/EUDA-Health-Holdings-Ltd.png" alt="" original-src="https://ml.globenewswire.com/media/YWMyYmUxYjMtNDRhMS00NWRjLWJiOGMtNGQwNDFiYWZlNmYxLTUwMDEyNDQzOS0yMDI2LTAxLTEzLWVu/tiny/EUDA-Health-Holdings-Ltd.png"/></p>

Euda Health 与深圳 Inno 签署可转换贷款协议，进一步扩展其干细胞治疗平台 | Euda Health 股票新闻